Nasopharyngeal carriage rate, antimicrobial resistance and serotype distribution of Streptococcus pneumoniae among children with upper respiratory infection
YU Sang-Jie, GAO Wei, SHI Wei, YUAN Lin, SHEN A-Dong, YAO Kai-Hu, YANG Yong-Hong
Key Laboratory of Major Diseases in Children and National Key Discipline of Pediatrics, Ministry of Education, Microbiological Laboratory in Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, Beijing 100045,China
Abstract Objective To investigate nasopharyngeal carriage rate, antimicrobial resistance and serotype distribution of Streptococcus pneumoniae among children with upper respiratory infection. Methods Nasopharygeal swabs were collected from children with upper respiratory infection visiting the outpatient department of Beijing Children's Hospital between March 2013 and February 2014. The antibiotic susceptibility was tested by Etest method, and the serotype was determined by Quellung reaction. Results The nasopharyngeal carriage rate for Streptococcus pneumoniae was 23.8% (699/2 941). One hundred isolates were randomly chosen for antimicrobial susceptiblity test and serotyping. Up to 98.0% isolates were susceptible to parenteral penicillin. The susceptible rate against oral penicillin, however, was 33.0%. The non-susceptible rate to erythromycin and azithromycin was 97.0%. The multi-drug resistance rate was up to 86.0%. The common serotypes were 6A(12.0%), 19F(12.0%), 6B(10.0%), 23F(9.0%) and 14(8.0%). The coverage rates of 7-, 10- and 13-valent pneumococcal conjugate vaccine were 41.0%, 42.0% and 59.0% respectively. Conclusions About 25% of children with upper respiratory infection are nasopharyngeal colonized by Streptococcus pneumoniae. The isolates show a high antimicrobial resistance. The 13-valent pneumococcal conjugate vaccine covers about 60.0% of the isolates.
YU Sang-Jie,GAO Wei,SHI Wei et al. Nasopharyngeal carriage rate, antimicrobial resistance and serotype distribution of Streptococcus pneumoniae among children with upper respiratory infection[J]. CJCP, 2014, 16(10): 988-992.
YU Sang-Jie,GAO Wei,SHI Wei et al. Nasopharyngeal carriage rate, antimicrobial resistance and serotype distribution of Streptococcus pneumoniae among children with upper respiratory infection[J]. CJCP, 2014, 16(10): 988-992.
Scott JR, Millar EV, Lipsitch M, et al. Impact of more than adecade of pneumococcal conjugate vaccine use on carriage andinvasive potential in Native American communities[J]. J InfectDis, 2012, 205(2): 280-288.
[2]
Sharma D, Baughman W, Holst A, et al. Pneumococcal carriageand invasive disease in children before introduction of the13-valent conjugate vaccine: comparison with the era before7-valent conjugate vaccine[J]. Pediatr Infect Dis J, 2013, 32(2):e45-53.
Sørensen UB. Typing of pneumococci by using 12 pooledantisera[J]. J Clin Microbiol, 1993, 31(8): 2097-2100.
[5]
Clinical and Laboratory Standards Institute. M100-S22.Performance standards for antimicrobial susceptibility testing;Twenty-second informational supplement[S]. CLSI, 2012.
Zhou L, Yu SJ, Gao W, et al. Serotype distribution and antibioticresistance of 140 pneumococcal isolates from pediatric patientswith upper respiratory infections in Beijing, 2010[J]. Vaccine,2011, 29(44): 7704-7710.
[9]
Mayanskiy N, Alyabieva N, Ponomarenko O, et al. Serotypesand antibiotic resistance of non-invasive Streptococcuspneumoniae circulating in pediatric hospitals in Moscow,Russia[J]. Int J Infect Dis, 2014, 20: 58-62.
[10]
Yao KH, Yang YH. Streptococcus pneumoniae diseases inChinese children: past, present and future[J]. Vaccine, 2008, 26(35): 4425-4433.
[11]
Xue L, Yao KH, Xie GL, et al. Serotype distribution andantimicrobial resistance of Streptococcus pneumoniae isolatesthat cause invasive disease among Chinese children[J]. ClinInfect Dis, 2010, 50(1) : 741-744.
[12]
Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline inpneumonia admissions after routine childhood immunisationwith pneumococcal conjugate vaccine in the USA: a time-seriesanalysis[J]. Lancet, 2007, 369(9568): 1179-1186.
[13]
Cutts FT, Zaman SM, Enwere G, et al. Gambian PneumococcalVaccine Trial Group. Efficacy of nine-valent pneumococcalconjugate vaccine against pneumonia and invasivepneumococcal disease in the Gambia: randomised, double-blind,placebo-controlled trial[J]. Lancet, 2005, 365(9465): 1139-1146.
[14]
Dagan R. Impact of pneumococcal conjugate vaccine oninfections caused by antibiotic-resistant Streptococcuspneumoniae[J]. Clin Microbiol Infect, 2009, 3(15): 16-20.
[15]
Liñares J, Ardanuy C, Pallares R, et al. Changes in antimicrobialresistance, serotypes and genotypes in Streptococcuspneumoniaeover a 30-year period[J]. Clin Microbiol Infect,2010, 16(5): 402-410.